RUNX2 and osteoporosis: As it was shown that the inhibition of DPPIV activity leads to an increase in GLP-1 levels and that this hormone can inhibit sclerostin and activate the Wnt/β-catenin/RUNX2 molecular pathway [232], we hypothesize that the biological effects exerted by the nutraceutical GliceFen® could also counteract the detrimental effects of osteoporosis (Figure 3).